Embolus Prevention: Anticoagulant Therapy in Comparison to Watchman\u27s Procedure in Patients with Atrial Fibrillation by Fladmo, Erik
University of North Dakota
UND Scholarly Commons
Physician Assistant Scholarly Project Posters Department of Physician Studies
2019
Embolus Prevention: Anticoagulant Therapy in
Comparison to Watchman's Procedure in Patients
with Atrial Fibrillation
Erik Fladmo
University of North Dakota
Follow this and additional works at: https://commons.und.edu/pas-grad-posters
Part of the Cardiovascular Diseases Commons
This Poster is brought to you for free and open access by the Department of Physician Studies at UND Scholarly Commons. It has been accepted for
inclusion in Physician Assistant Scholarly Project Posters by an authorized administrator of UND Scholarly Commons. For more information, please
contact zeineb.yousif@library.und.edu.
Recommended Citation
Fladmo, Erik, "Embolus Prevention: Anticoagulant Therapy in Comparison to Watchman's Procedure in Patients with Atrial
Fibrillation" (2019). Physician Assistant Scholarly Project Posters. 138.
https://commons.und.edu/pas-grad-posters/138
Embolus Prevention: Anticoagulant Therapy In Comparison To Watchman’s 
Procedure In Patients With Atrial Fibrillation
Erik Fladmo PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Abstract
• Anticoagulant therapy has been a mainstay treatment for 
patients who have a-fib for prevention of blood clots.
• With use of an oral and or non-oral anticoagulant the 
patient’s risk for developing a thrombus or embolus is 
markedly diminished. 
• Risks involved by taking oral or non-oral anticoagulants: 
prolonged bleeding, increased bruising, hemorrhagic stroke.
• In 2015 the FDA approved the Watchman’s procedure. This 
procedure entails the insertion of a closure device into the 
left atrial appendage of the left atrium to block blood clots 
before they exit due to a-fib. The purpose of this study will 
be to review both long term anticoagulant therapy and the 
Watchman device as prophylactic treatments, as well as the 
difference between the two regarding their purpose, in 
addition to comparing their of costs, risks, and benefits. 
STATEMENT OF THE PROBLEM
• Warfarin a commonly used anticoagulant needs constant 
monitoring due to narrow therapeutic index. Patients need 
to be very compliant for the full benefit of preventing blood 
clots (Katritsis, Gersh, & Camm, 2015). 
• Factor Xa inhibitors have fixed dosing, lower interactions, 
and they do not require monitoring in clinic via INR 
(Katritsis, Gersh, & Camm, 2015). 
Literature Review
Discussion
Introduction
Clinical Application
• Atrial fibrillation or A-fib is a common cardiac disease that 
occurs     as individuals get older.  
• A risk factor of atrial fibrillation is blood clot formation and 
dislodgement or ‘embolus’ in the left atrium. 
• Current treatment methods to prevent clot formation 
include anticoagulants, as well as a left atrial appendage 
closure device, The Watchman’s device is the only FDA 
approved left atrial appendage closure device. 
• Study results confirm the rising efficacy and cost 
effectiveness of Watchman’s device versus long term 
anticoagulant therapy as well as their adverse effects 
regarding placement and post procedure; however further 
randomized control trials are needed to compare both 
therapies particularly novel oral anticoagulants head to 
head rather than through extrapolation. 
• Long term effects of Watchman’s device need to be 
studied. 
RESEARCH QUESTIONS
• For prevention of embolus formation from atrial fibrillation 
in the adult and older adult population, would 
anticoagulant therapy or Watchman procedure be a 
better choice? 
• When comparing Watchman’s procedure and long-term 
anti-coagulant therapy for eligible patients, which choice 
would be the best economically for the patient? 
• A-fib, according to Markides & Shilling (2003) is caused 
by combined micro-reentry action potential with 
enhanced automaticity in the heart. The heart fibrillates 
and loses regular contraction.
• According to Pellman, Sheikh, Diego, & Jolla (2017) 
blood coagulates in a fibrillating heart forming embolism.
• Many patients who take anticoagulants run the risk of 
bleeding and increased costs due to appointments and 
medication refills. Watchman’s device, a relatively new 
treatment in preventing embolus or blood clots in the heart, 
needs to be considered for patients who suffer from atrial 
fibrillation.
• A-fib is diagnosed by 12-lead EKG (Guitierrez & 
Blanchard, 2016). 
• Use of anticoagulation is based on CHADS2 and 
CHA2DS2-VASc for eligible patients (Markides & 
Schilling, 2003).
• Markides & Schilling (2003) show that anticoagulants 
can prevent clots, however there is an increased risk in 
bleeding and hemorrhagic stroke.
• There are many anticoagulants on the market today, 
each has an effect on different areas of the coagulation 
cascade (Harter, Levine, & Henderson, 2015). 
• Most common anticoagulants to prevent embolus are 
Aspirin, Warfarin, and Factor Xa inhibitors ala Eliquis. 
• Factor Xa inhibitors cost more as compared to 
Warfarin (Katritsis, Gersh, & Camm, 2015). 
• Direct thrombin inhibitors are as effective as warfarin 
in preventing stroke and embolus  with fewer 
intercranial bleeds 0.30% vs. 0.74% per year 
(Gutierrez & Blanchard, 2016). 
• The Watchman Device prevents potential clots in 
patients with A-fib by blocking the left atrial appendage 
or LAA where 90% of emboli form (Sharma, Park, & 
Lakkireddy, 2018).
• FDA approved since March 2015. Placement of the 
device is made under general anesthetic.
• Watchman device has been shown to be superior to 
warfarin in preventing hemorrhagic stroke (HR: 0.20, 
95% CI: 0.07 to 0.56; (p=0.0022). As well as 
disabling/fatal stroke, cardiovascular or unexplained 
death (Reddy et al. 2017). 
• When Watchman(OR 0.21 CI 0.05-0.99)  and Newer 
oral anticoagulants (NOACs) (OR 0.46 CI 0.30-0.82)  
were compared overall results showed superiority over 
Warfarin in hemorrhaging stroke (Koifman et al., 
2016).
• NOACs showed a higher likelihood of hemorrhagic 
stroke as compared to Watchman’s device though 
(OR 0.44, CI 0.09-2.14) (Koifman et al., 2016).
• Watchman cost is higher than warfarin/NOAC initially, 
however at 10 years LAAC has more quality-adjusted life 
years with lower totaling costs (Reddy et al.,2018). LAAC 
was shown to be the most cost-effective treatment strategy 
for prevention of stroke in a-fib (Reddy et al.,2018).
• Anticoagulation therapy and Watchman’s device both have 
risks upon implementation regarding A-fib.
• Watchman’s procedure has pre and post surgical risk. 
• Procedures have improved with practice via a decrease in 
complications 8.7% to 4.2%, and since FDA approval 
(Sharma, Park, & Lakkireddy, 2018).
• Indirect comparison shows NOACs and Watchman are 
superior to Warfarin for hemorrhagic stroke prevention 
(Koifman et al., 2016).
• Watchman’s device decreases/eliminates risk of bleed, 
decreased cost, and constant monitoring (Harter, Levine, & 
Henderson, 2015).
• Hemorrhage is still the most feared adverse effect with 
anticoagulants (Harter, Levine, & Henderson, 2015).
• There are very few studies comparing Watchman’s device 
to NOACs. Based on indirect comparison both NOACs and 
Watchman Device are superior to Warfarin in hemorrhagic 
stroke prevention. 
• According to Koifman et al., 2016 NOACs have a higher 
rate of hemorrhagic stroke (OR 0.44, CI 0.09-2.14) as 
compared to Watchman’s device. Watchman’s device 
displayed higher occurrence of ischemic stroke as 
compared to NOACs though.
• Ischemic strokes have been shown to be non-disabling and 
result in functional independence overall (Reddy et al., 
2016). 
• Cost effectiveness of Watchman’s device is shown at 5 
years post procedure as compared to NOACs and warfarin. 
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• Antiplatelets compared to Warfarin showed less protection 
and increased relative risk of 1.44 for stroke, PE, MI, and 
vascular death (Katritsis, Gersh, & Camm, 2015).
References
• There is not a end all medicine/application to prevent stroke in 
patients with a-fib.
• Watchman’s device has a decreased rate of bleeding, 
hemorrhagic stroke, and shows. non-inferiority to 
anticoagulants (warfarin) and ease of compliance are all 
benefits that a patient needs to be educated on when 
considering embolus prevention/anticoagulation prevention in 
A-fib. 
• Watchman’s procedure and implementation has become more 
refined and practitioners are better trained as well. 
• More RCT are needed for comparison to NOACs to fully 
encompass efficacy vs. adverse effects. 
Guiterrez, C., & Blanchard, D. G. (2016). Diagnosis and treatment of atrial fibrillation. American Family Physician, 94(6), 442–452.      
https://doi.org/10.1111/j.2042-3292.1999.tb00910. 
Harter, K., Levine, M., & Henderson, S. (2015). Anticoagulation drug therapy: A review. Western Journal of Emergency Medicine, 16(1), 11–
17. https://doi.org/10.5811/westjem.2014.12.22933 
Katritsis, D. G., Gersh, B. J., & Camm, A. J. (2015). Anticoagulation in atrial fibrillation – current concepts. Arrhythmia & Electrophysiology 
Review, 04(2), 100. https://doi.org/10.15420/AER.2015.04.02.100
Koifman, E., Lipinski, M. J., Escarcega, R.O., Didier, R., Kiramijyan, S., Torguson, R., & Waksman, R. (2016). Comparison of watchman 
device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis. International Journal of Cardiology, 
205, 17–22. https://doi.org/10.1016/j.ijcard.2015.11.181
Markides, V., & Schilling, R. J. (2003). Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart (British Cardiac 
Society), 89(8), 939–943. https://doi.org/10.1136/heart.89.8.939
Pellman, J., Sheikh, F., Diego, S., & Jolla, L. (2017). Atrial fibrillation: Mechanisms, therapeutics, and future directions. Comprehensive
Physiology. 5(2), 649–665. https://doi.org/10.1002/cphy.c140047.Atrial
Reddy, V. Y., Akehurst, R. L., Armstrong, S. O., Amorosi, S. L., Brereton, N., Hertz, D. S., & Holmes, D. R. (2016). Cost effectiveness of left 
atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.
Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, 
Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology, 18(7), 979–986. 
https://doi.org/10.1093/europace/euv412
Reddy, V. Y., Doshi, S. K., Kar, S., Gibson, D. N., Price, M. J., Huber, K., … Holmes, D. R. (2017). 5-Year outcomes after left atrial appendage 
closure: From the PREVAIL and PROTECT AF trials. Journal of the American College of Cardiology, 70(24), 2964–2975. 
https://doi.org/10.1016/j.jacc.2017.10.021
Reddy, Vivek Y.; Akehurst, Ronald L.; Amorosi, Stacey L.; Gavaghan, Meghan; Hertz, Deanna S.; Holmes, D. R. (2018). Cost-effectiveness of 
left atrial appendage closure with the WATCHMAN device compared with warfarin or non-vitamin k antagonist oral anticoagulants 
for secondary prevention in nonvalvular atrial fibrillation.pdf. Stroke, 49, 1464–1470. Retrieved from 
https://www.ahajournals.org/doi/10.1161/STROKEAHA.117.018825
Sharma, S. P., Park, P., & Lakkireddy, D. (2018). Left atrial appendages occlusion: Current status and prospective. Korean Circulation 
Journal, 48(8), 692. https://doi.org/10.4070/kcj.2018.0231
